200 related articles for article (PubMed ID: 25535978)
81. Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics.
Rashid MM; Lee H; Jung BH
Sci Rep; 2020 Oct; 10(1):17523. PubMed ID: 33067464
[TBL] [Abstract][Full Text] [Related]
82. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma.
Fang C; Xie H; Zhao J; Wang W; Hou H; Zhang B; Zhou D; Geng X
Anticancer Drugs; 2021 Sep; 32(8):822-828. PubMed ID: 33783376
[TBL] [Abstract][Full Text] [Related]
83. [Effect of Huaier Aqueous Extract Combined with Routine Chemo-therapeutic Drugs on Human Acute Lymphoblastic Leukemia Cells Nalm-6 and Sup-B15].
Qu P; Zhou F; Tan LF; Wang ZJ; Wang ML; Jin RM; Han J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1451-1458. PubMed ID: 33067936
[TBL] [Abstract][Full Text] [Related]
84. [Combination of PP242 and dasatinib suppresses the progression of acute myeloid leukemia in a mouse model].
Qu YH; Liu HT; He FC
Zhonghua Yi Xue Za Zhi; 2017 May; 97(20):1584-1588. PubMed ID: 28592067
[No Abstract] [Full Text] [Related]
85. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia.
Grüninger PK; Uhl F; Herzog H; Gentile G; Andrade-Martinez M; Schmidt T; Han K; Morgens DW; Bassik MC; Cleary ML; Gorka O; Zeiser R; Groß O; Duque-Afonso J
Cancer Gene Ther; 2022 Nov; 29(11):1751-1760. PubMed ID: 35794338
[TBL] [Abstract][Full Text] [Related]
86. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Hoang B; Frost P; Shi Y; Belanger E; Benavides A; Pezeshkpour G; Cappia S; Guglielmelli T; Gera J; Lichtenstein A
Blood; 2010 Nov; 116(22):4560-8. PubMed ID: 20686120
[TBL] [Abstract][Full Text] [Related]
87. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
[TBL] [Abstract][Full Text] [Related]
88. MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2.
Liu Y; Lei P; Qiao H; Sun K; Lu X; Bao F; Yu R; Lian C; Li Y; Chen W; Xue F
J Cell Biochem; 2020 Jan; 121(1):385-393. PubMed ID: 31222822
[TBL] [Abstract][Full Text] [Related]
89. Distinct perturbation of the translatome by the antidiabetic drug metformin.
Larsson O; Morita M; Topisirovic I; Alain T; Blouin MJ; Pollak M; Sonenberg N
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8977-82. PubMed ID: 22611195
[TBL] [Abstract][Full Text] [Related]
90. Diallyl disulfide induces apoptosis and autophagy via mTOR pathway in myeloid leukemic cell line.
Suangtamai T; Tanyong DI
Tumour Biol; 2016 Aug; 37(8):10993-9. PubMed ID: 26891668
[TBL] [Abstract][Full Text] [Related]
91. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Ikezoe T; Nishioka C; Tasaka T; Yang Y; Komatsu N; Togitani K; Koeffler HP; Taguchi H
Mol Cancer Ther; 2006 Oct; 5(10):2522-30. PubMed ID: 17041096
[TBL] [Abstract][Full Text] [Related]
92. eIF4E is a critical regulator of human papillomavirus (HPV)-immortalized cervical epithelial (H8) cell growth induced by nicotine.
Chen L; Wang H
Toxicology; 2019 May; 419():1-10. PubMed ID: 30836163
[TBL] [Abstract][Full Text] [Related]
93. Dual modulation of MCL-1 and mTOR determines the response to sunitinib.
Elgendy M; Abdel-Aziz AK; Renne SL; Bornaghi V; Procopio G; Colecchia M; Kanesvaran R; Toh CK; Bossi D; Pallavicini I; Perez-Gracia JL; Lozano MD; Giandomenico V; Mercurio C; Lanfrancone L; Fazio N; Nole F; Teh BT; Renne G; Minucci S
J Clin Invest; 2017 Jan; 127(1):153-168. PubMed ID: 27893461
[TBL] [Abstract][Full Text] [Related]
94. Administration of dexamethasone disrupts endometrial receptivity by alteration of expression of miRNA 223, 200a, LIF, Muc1, SGK1, and ENaC via the ERK1/2-mTOR pathway.
Shariati MBH; Niknafs B; Seghinsara AM; Shokrzadeh N; Alivand MR
J Cell Physiol; 2019 Nov; 234(11):19629-19639. PubMed ID: 30993706
[TBL] [Abstract][Full Text] [Related]
95. miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis.
Liu Y; Lei P; Qiao H; Sun K; Lu X; Bao F; Yu R; Lian C; Li Y; Chen W; Xue F
Int J Biol Sci; 2019; 15(3):579-586. PubMed ID: 30745844
[TBL] [Abstract][Full Text] [Related]
96. Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling.
Long H; Hou Y; Li J; Song C; Ge Z
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047788
[TBL] [Abstract][Full Text] [Related]
97. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
Pan J; Chen C; Jin Y; Fuentes-Mattei E; Velazquez-Tores G; Benito JM; Konopleva M; Andreeff M; Lee MH; Yeung SC
Cell Cycle; 2012 Jun; 11(12):2314-26. PubMed ID: 22659796
[TBL] [Abstract][Full Text] [Related]
98. The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
Becker MN; Wu KJ; Marlow LA; Kreinest PA; Vonroemeling CA; Copland JA; Williams CR
Urol Oncol; 2014 Apr; 32(3):317-26. PubMed ID: 24054871
[TBL] [Abstract][Full Text] [Related]
99. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism.
Liu LL; Long ZJ; Wang LX; Zheng FM; Fang ZG; Yan M; Xu DF; Chen JJ; Wang SW; Lin DJ; Liu Q
Mol Cancer Res; 2013 Nov; 11(11):1326-36. PubMed ID: 24008673
[TBL] [Abstract][Full Text] [Related]
100. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.
Srivastava RK; Li C; Khan J; Banerjee NS; Chow LT; Athar M
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24583-24592. PubMed ID: 31732667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
